Leiomyosarcoma of Soft Tissue

Leiomyosarcoma is a malignant tumour that shows differentiation toward smooth muscle, and it is one of the more common adult soft tissue sarcomas. In soft tissue it arises wherever smooth muscle exists: in the walls of blood vessels, in the dermal arrector pili muscles, in the viscera, and from poorly differentiated mesenchymal cells.

The three clinical groups. The three clinically important groups are:

• Somatic soft tissue of the extremity and trunk - a deep mass, often resectable, with the best access to wide margins
• Retroperitoneal and abdominal - large at diagnosis, with difficult margins and worse survival
• Large vessels, such as the inferior vena cava - arising from the vessel-wall smooth muscle, with distinct behaviour

Who. Most patients are middle-aged to older adults, typically 50-70 years, with a slight overall female predominance that is strong in uterine disease. Leiomyosarcoma makes up roughly 10-20% of adult soft tissue sarcomas. Young patients are uncommon but possible, so consider it in any persistent deep mass.

Where. The extremity and trunk are the common somatic soft tissue site, and these tumours are often deep. The retroperitoneum and abdomen are frequent and prognostically poor, because the tumours are large and the margins hard to obtain. Vascular tumours of the inferior vena cava and other vessels form a distinct group arising from the vessel wall, and cutaneous or subcutaneous tumours are smaller, with a better prognosis when superficial.

Outcome by site. In the MSKCC series of primary leiomyosarcoma the three site groups behaved differently, and the differences are largely explained by size and margins:

Vascular leiomyosarcoma of the inferior vena cava. Leiomyosarcoma is the commonest primary malignant tumour of the inferior vena cava, arising from the vessel-wall smooth muscle, with a marked female predominance. It is classified by the level of caval involvement, which dictates presentation and reconstruction:

• Level I (lower, infrarenal) - below the renal veins. Often presents with leg swelling; the abundant collaterals that develop may allow ligation without reconstruction
• Level II (middle, renal-to-hepatic) - between the renal and hepatic veins, and the commonest level. Renal vein involvement matters, and reconstruction with a graft is often needed to preserve renal outflow
• Level III (upper, suprahepatic) - at or above the hepatic veins, up to the right atrium. Presents with Budd-Chiari syndrome (hepatic venous outflow obstruction); technically the hardest, and may need cardiopulmonary bypass

Management is en bloc resection of the involved caval segment with reconstruction (ring-reinforced PTFE or graft) or ligation, depending on level and collateral development. Prognosis is worse than extremity disease, and the liver and lung are the metastatic sites.

Genetics. Unlike synovial sarcoma or Ewing sarcoma, leiomyosarcoma has no single recurrent translocation and no pathognomonic fusion gene. It shows a complex, unstable karyotype instead: numerous copy-number changes and chromosomal rearrangements, widespread chromosomal gains and losses, and frequent loss of tumour-suppressor function (for example the RB1 and TP53 pathways). The biology is heterogeneous between uterine and non-uterine tumours.

Why there is no targeted drug. This genomic complexity is typical of the "non-translocation" pleomorphic sarcomas, and it explains why no targeted driver therapy, such as imatinib for GIST, exists. Nor is there a single confirmatory molecular test: the diagnosis combines characteristic histology with a smooth-muscle immunoprofile, set out in the next section, with GIST excluded by KIT and DOG1 for visceral lesions and dedifferentiated liposarcoma with smooth-muscle areas excluded in the retroperitoneum.

Growth and local behaviour. The tumour is an enlarging deep mass, often painless until large, so diagnostic delay is common and any deep mass over 5cm needs urgent imaging. Locally it is infiltrative, pushing and invading along fascial planes, which is why wide margins are essential to control local recurrence.

Spread. Metastasis is predominantly haematogenous and lymph-node spread is uncommon, so staging looks at the lungs, and at the liver for retroperitoneal and vascular tumours. Recurrence can occur beyond 5 years, especially in retroperitoneal disease, and long-term surveillance is mandatory.

Histological Diagnosis

Morphology. Leiomyosarcoma is built from long, sweeping fascicles of spindle cells that intersect at roughly right angles. The classic clue is the blunt-ended (cigar-shaped) nucleus, set in brightly eosinophilic, fibrillary cytoplasm; perinuclear vacuoles may be seen. Mitoses are present and atypia varies with grade: higher-grade tumours show pleomorphism and necrosis, with pleomorphic or dedifferentiated areas, and coagulative tumour necrosis contributes to the grade.

View larger

View larger

Immunohistochemistry. Smooth-muscle markers establish the line of differentiation, but no single marker is fully specific, so a panel plus morphology is required. Two or more smooth-muscle markers in a pleomorphic spindle-cell tumour are what separate leiomyosarcoma from undifferentiated pleomorphic sarcoma.

View larger

Differential diagnosis. The mimics are separated by site, morphology and a small number of discriminating tests:

The retroperitoneal trap. In the retroperitoneum a spindle-cell tumour with smooth-muscle areas may actually be a dedifferentiated liposarcoma, so always consider MDM2/CDK4 testing and sample the specimen widely before committing to a leiomyosarcoma diagnosis.

FNCLCC Histological Grading

Grade is the single most important histopathological prognostic factor in soft tissue sarcoma. The FNCLCC (French Federation of Cancer Centres) system assigns a grade from a score built on three components, and the total score maps to grade 1, 2 or 3. High grade (grade 3) is independently associated with distant recurrence and death, and grade drives systemic risk far more than tumour size.

View larger

AJCC Staging (Soft Tissue Sarcoma)

Retroperitoneal sarcomas use a separate AJCC size-banded staging scheme. Most clinically significant leiomyosarcomas are intermediate to high grade.

History. Presentation follows the site. An extremity or trunk tumour is an enlarging, often painless deep mass; a retroperitoneal tumour brings vague abdominal fullness, pain and mass effect; a vascular (IVC) tumour presents with leg swelling, Budd-Chiari features or abdominal pain; a cutaneous tumour is a small, firm dermal or subcutaneous nodule.

Red flags. Four features of any soft tissue mass demand attention:

• Size greater than 5cm
• Deep to fascia
• Increasing in size
• New pain in a previously painless lump

Examination. Inspect for the size of the mass and its relation to surface anatomy; skin changes are uncommon unless the tumour is cutaneous or fungating, and limb swelling or venous engorgement occur with vascular tumours. On palpation a deep tumour is firm and often fixed; record its relation to the neurovascular bundle, and tenderness, seen with large or nerve-involving tumours.

Function, nodes and chest. Test the joint range of motion if the mass is periarticular, the distal neurovascular status and the muscle power in the affected compartment. Examine the regional nodes (metastasis there is uncommon, but it is recorded) and the chest, since the lung is the dominant metastatic site. A complete baseline supports later treatment planning.

View larger

The three modalities. Surgery means wide excision with a cuff of normal tissue, the biopsy tract excised en bloc. Radiotherapy is given pre- or post-operatively for deep or larger extremity tumours or for close margins. Systemic therapy is doxorubicin-based for advanced disease and is not routine adjuvant treatment. These principles apply across leiomyosarcoma sites, modified by anatomy, and the intensity of each is set by site, resectability and stage:

Systemic Agents in Advanced Leiomyosarcoma

Planning. Review the MRI and CT with radiology and the sarcoma MDT to define the tumour extent and its neurovascular relations, confirm the diagnosis and grade on the core biopsy, and plan the resection margins and the reconstruction. Mark the biopsy tract for en bloc excision, plan a longitudinal, extensile incision, and treat drain sites as contaminated. Anticipate the soft tissue defect, arrange flap or graft coverage if needed, and plan vascular reconstruction for vessel-based tumours; good planning underpins both oncological clearance and function.

Exposure and en bloc excision. Through a longitudinal incision incorporating the biopsy tract, gain proximal and distal neurovascular control and confirm the tumour extent against the MRI. Remove the tumour with a cuff of normal tissue and the biopsy tract. Preserve major vessels and nerves if they are not encased, and sacrifice or reconstruct structures where needed for clearance: preserving a nerve that runs through tumour converts a wide margin into a positive one.

View larger

Specimen orientation. Mark the margins with sutures and orient the specimen for pathology, requesting assessment of all margins and the final grade.

Reconstruction and closure. Close primarily, with a local flap or with free tissue transfer as required; drain the dead space and plan early rehabilitation, because functional reconstruction matters for quality of life. Reconstruction is planned before the excision so that margins are never compromised for closure. The technique is chosen on defect size, exposed bone or tendon, prior radiotherapy, local tissue availability and comorbidity, not on a surgeon's preference for a single method.

View larger

View larger

View larger

Margins and Re-excision

What decides outcome. In primary leiomyosarcoma, multivariate analysis shows that grade and size are the dominant independent predictors of disease-specific survival and distant recurrence, while margin status drives local recurrence. Grade, not size alone, is the variable that changes the systemic treatment discussion. Retroperitoneal tumours do worse than extremity tumours, but much of that difference is explained by their larger size and the difficulty of obtaining clear margins.

View larger

View larger

Depth in superficial disease. Superficial leiomyosarcoma is not one entity: the depth relative to the dermis splits it into two prognostically very different tumours, a classic examiner discriminator. Cutaneous (dermal) leiomyosarcoma arises from the arrector pili (pilar) smooth muscle in the dermis; it is essentially non-metastasising, the concern is local recurrence only, the prognosis is excellent and wide local excision is curative, so intensive systemic staging and surveillance are largely unnecessary. Subcutaneous leiomyosarcoma arises from vessel-wall smooth muscle in the subcutis; it behaves like a deep soft tissue sarcoma and does metastasise, to the lung, so it needs wide margins plus staging and long-term surveillance like other deep tumours.

The dividing line is the dermis. A tumour confined to the dermis behaves benignly as far as metastasis is concerned, whereas one that involves or sits beneath the subcutis carries true metastatic risk, and that dichotomy sets the extent of staging, follow-up and counselling.

Follow-up is front-loaded because the risk is, and it never quite ends because the disease can return late. The schedule is a protocol:

How the imaging is read. Response and progression are judged on the same modality at each timepoint, with identical lung and mediastinal windows, so that small changes in a lesion are measurable; that is how partial response and progression are actually determined. Whole-body MRI is a radiation-sparing follow-up option, particularly in younger patients.

View larger

View larger

Global Epidemiology

Side-by-Side Guidance from Major Societies

High- vs Limited-Resource Practice Variation

Adjuvant chemotherapy. The benefit of adjuvant chemotherapy in resected soft tissue sarcoma remains unproven. The EORTC 62931 randomised trial of doxorubicin plus ifosfamide showed no relapse-free or overall survival benefit, so chemotherapy is not routine and is reserved for selected high-risk cases at MDT discretion.

Histology-driven systemic therapy. Second-line therapy is becoming histology-specific. Trabectedin genuinely has activity in leiomyosarcoma (and liposarcoma). Eribulin is the caution: its phase III survival benefit was driven by the liposarcoma subgroup and is not established for leiomyosarcoma, so quoting it as a leiomyosarcoma agent overstates the evidence. Pazopanib fills part of that gap for non-adipocytic sarcoma, though with progression-free and not overall-survival benefit, and the optimal sequencing remains debated.

Radiotherapy in retroperitoneal disease. Radiotherapy is well established for deep extremity sarcoma, but its role in the retroperitoneum is contested, with trial data showing limited benefit. Use is selective and individualised.

Lung metastasectomy. Resection of resectable, oligometastatic lung disease is widely practised and associated with longer survival in selected patients, but no randomised trial confirms a survival benefit. Patient selection is decisive.